Clinical Trials Logo

Parkinson Disease(PD) clinical trials

View clinical trials related to Parkinson Disease(PD).

Filter by:

NCT ID: NCT06245174 Recruiting - Clinical trials for Parkinson Disease(PD)

A Smartphone Application for Neurology and Telemedicine

NeuroVision
Start date: May 11, 2023
Phase:
Study type: Observational

This observational research study is designed to assess the feasibility of developing a new software application that can be used in the home using a commercially available camera to measure abnormal body movements associated with Parkinson's disease (PD). The goal of this study is to validate the motor outcomes derived from a consumer camera observing a sub-set of standardized assessment tasks with respect to the reference motion capture system.

NCT ID: NCT05395624 Recruiting - Clinical trials for Amyotrophic Lateral Sclerosis (ALS)

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

Start date: February 2, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.

NCT ID: NCT05113524 Completed - Clinical trials for Parkinson Disease(PD)

Effects of Dance on the Turning Characteristics of Patients With Parkinson's Disease

Start date: December 10, 2018
Phase: N/A
Study type: Interventional

The proposed control intervention trial, aims to analyse the effects of Dance in the turning characteristics in patients with Parkinson Disease (PD) using three- dimensional (3D) analysis during the timed up and go (TUG) test.

NCT ID: NCT05033912 Withdrawn - Clinical trials for Mild Cognitive Impairment (MCI)

A Study of CST-2032 in Subjects With Cognitive Impairment

Start date: October 2021
Phase: Phase 1
Study type: Interventional

This study will evaluate the effects of CST-2032 when administered with pre-administered CST-107 on safety, tolerability, cognition, cerebral perfusion, and cerebral metabolism in patients with cognitive impairment.

NCT ID: NCT04748263 Completed - Clinical trials for Alzheimer's Dementia

Eye Gaze Strategies During Facial Emotion Recognition in Neurodegenerative Diseases: Links With Neuropsychiatric Disorders (EYE-ToM Study)

EYE-ToM
Start date: July 1, 2015
Phase:
Study type: Observational

It is commonly admitted that social cognition impairment, like deficit in facial emotion recognition or misinterpretation of others' intentions (Theory of Mind), are associated with social behavior disorders. This kind of disorders are observed in Fronto-Temporal Dementia (FTD), Alzheimer's Dementia (AD) and Parkinson's Disease (PD), with severe deficits in FTD and lighter deficits in AD and PD. One explanation might be that patients apply inappropriate visual exploration strategies to decode emotions and intentions of others. This study aims to test this hypothesis and further to analyse whether different patterns emerge from these pathologies.

NCT ID: NCT04193527 Completed - Essential Tremor Clinical Trials

A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients

Start date: June 28, 2020
Phase: Phase 3
Study type: Interventional

This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical diagnosis of Parkinsonian syndrome (PS) involving striatal dopaminergic deficit (SDD; specifically, Parkinson's disease [PD] [SDD], multiple system atrophy [MSA] [SDD] or or progressive supranuclear palsy [PSP] [SDD]) as compared with patients with a clinical diagnosis of essential tremor (ET) (no SDD) and age-matched healthy controls.

NCT ID: NCT04041193 Active, not recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

An Innovative Disease-net Management Model for Non-communicable Diseases (SIDERA^B)

SIDERA^B
Start date: July 29, 2019
Phase: N/A
Study type: Interventional

The SIDERA^B telerehabilitation system is enabled by a multi-domain, multi-device platform providing at home multi-component rehabilitation, targeting cardiovascular (Chronic Heart Failure, CHF), pulmonary (Chronic Obstructive Pulmonary Disease, COPD) and neurodegenerative (Parkinson Disease, PD) chronic diseases. The rehabilitation program embeds engagement activities for patient and caregiver, to empower appropriation of the SIDERA^B care routines and fuel their well-being resources. The multidisciplinary layering of SIDERA^B is reflected in the validation protocol including a) clinical and well-being evaluation through a cross-over study confronting usual care with the SIDERA^B activities; b) technological evaluation: Health Technology Assessment for organizational, legal and equity impacts; c) economic evaluation: process mapping and budget impact analysis to define a sustainable reimbursement process for the innovative telerehabilitation pathway.

NCT ID: NCT03961282 Completed - Clinical trials for Parkinson Disease (PD)

CODY (Co-design for You): An Immersive Technology Tool for Experiencing and Assessing Home Alterations

Start date: May 25, 2019
Phase: N/A
Study type: Interventional

CODY (co-design for you) is a Virtual Reality (VR) tool and Application Programming Interface (API) which uses an immersive, interactive environment for using, experiencing and co-designing home alterations. The aim of this research is to assess the efficacy of using CODY to aid and enhance the ability of adults with Parkinson's disease (PD) to experience and choose appropriate home modifications.

NCT ID: NCT03840252 Completed - Clinical trials for Parkinson Disease (PD)

Progression of Striatal and Extrastriatal Degeneration in PD and PSP Patients

PARKONTHEWAY
Start date: September 23, 2015
Phase: N/A
Study type: Interventional

This longitudinal study aims to research cognitive and gait phenotypes of Parkinson's disease and Supranuclear Palsy as well as to provide markers to track diseases progression using a multi-modality approach based on 3D-gait analysis and MR Imaging. Specifically, this study want to identify cognitive pattern and gait-related cerebral diffusion/functional connectivity in PD and PSP patients and to verify their progression over a period of 18 months. In summary, the current protocol proposed to investigate the following issues: - to perform a multifactorial quantitative analysis of outcomes for PD and PSP compared to a control group in order to categorize cognitive and gait pattern in the group of patients and verify if the gait can be useful as discriminator for diagnosis. - to analyze whether diffusion and resting-state functional connectivity indices are correlated with clinical disease severity scores and motor scores and how they change over time (18 months later).

NCT ID: NCT02968433 Completed - Clinical trials for Parkinson Disease(PD)

The Stanford Parkinson's Disease Plasma Study

SPDP
Start date: November 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to demonstrate that young plasma infusions can be performed safely in patients with Parkinson's Disease (PD). Secondary outcomes will include behavioral and laboratory data that will support the next study that will inquire whether young plasma infusions improve or slow the progression of cognitive, mood and/or motor impairment and rate markers of the disease.